Get Started

We are pleased to welcome you to IG Launch

IG Launch is an innovative business division of IMRAT GROUP, dedicated to advancing groundbreaking solutions across technology and sustainability sectors.

Businesses worldwide Primer

Working with founders from the earliest stages, we actively invest in IPO and ICO markets. IG Launch's portfolio includes teams working on projects ranging from Tier 1 protocols and Web3 infrastructure to nanotechnology, decentralized finance, meta-universe and software.

We aim to be trusted strategic partners with a collaborative approach to investing. Our support includes not only funding, but also assistance with operational management, scaling, and building strategic partnerships.

We give teams access to our expertise in building efficient business processes, optimizing operations and leveraging key partners for market expansion.

What are ICOs and IPOs?

What is an ICO?

An ICO is a method of raising capital for cryptocurrency projects in which companies issue and sell their own tokens in exchange for investment. This process allows startups to raise funds quickly, bypassing traditional financial institutions, and gives investors access to promising new cryptocurrencies. ICOs are also called lunchepads - IG Launch actively participates in lunchepads. Earnings on lunchepads can reach up to 300% per year. After all, we are talking about investing in a company at the embryo stage, which can be equated to the construction of a multi-storey building, in which not even the ground floor is built! Investing at the very beginning is always a profitable investment. We analyse projects in depth to avoid the risk of a startup's collapse.

What is an ICO?
What is an IPO?

What is an IPO?

An IPO is a process whereby a private organisation offers its shares for sale to the general public on the stock market for the first time, giving investors a stake in the company and the right to a share of its profits. IPOs are highly regulated, require significant cost and preparation, and are usually targeted at large institutional investors. Unlike institutional investors, the key to our team's success lies in the speed of decision-making. The faster the buying decision is made, the bigger the earnings - this is our main motto.

*The main advantage of the chosen methods of raising capital is that the company gets resources to scale, and the investor gets an opportunity to buy shares or tokens at a low price. As the company grows, their value increases, which benefits both parties.

IG Launch history

  • (IZTC)

    Invizyne Technologies, Inc.

    About company

    Invizyne Technologies, Inc. operates as a synthetic biochemical company. Its SimplePath platform produces a range of chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds, as well as consists of a series of modular cascading enzyme based biomanufacturing systems that natural processes to perform chemical conversions.

    • Status: In progress

    • Investment period: November 2024 -

  • (XCH)

    XCHG Limited

    About company

    XCHG Limited, together with its subsidiaries, engages in designing, manufacturing, and selling of electric vehicle (EV) chargers under the X-Charge brand name in Europe, the People’s Republic of China, the United States, and internationally.

    The company offers direct current (DC) fast chargers under the C6 series and C7 series; and battery-integrated DC fast chargers under the Net Zero series, as well as software system upgrades and hardware maintenance services.

    • Status: Completed

    • Investment period: September 2024 - October 2024

    • Total return: 205,46%

  • (PGHL)

    Primega Group Holdings Ltd

    About company

    Primega Group Holdings Ltd. engages in the provision of transportation services through its subsidiary, Primega Construction. Its services include soil and rock transportation, diesel oil trading, and construction works such as excavation and lateral support works and bored piling. The company was founded on April 14, 2022 and is headquartered in Hong Kong.

    • Status: Completed

    • Investment period: July 2024 - September 2024

    • Total return: 116,81%

  • (ACTU)

    Actuate Therapeutics Inc

    About company

    Actuate’s lead drug, elraglusib (a novel GSK-3 inhibitor), targets multiple molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy. Elraglusib is also emerging as a mediator of anti-tumor immunity through the inhibition of multiple immune checkpoints and the regulation of immune cell function.

    • Status: Completed

    • Investment period: August 2024 - September 2024

    • Total return: -6,65%